Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

November 16, 2023 13:00 ET | Source: Oxurion NV

Oxurion Receives EUR 1.0 Million under Amended Atlas Funding Program Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Reach Topline Data from KALAHARI Trial This Year

Leuven, BELGIUM, Boston, MA, US – November 16, 2023 – 7 pm CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies,...
November 15, 2023 13:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – November 15, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
November 06, 2023 14:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
November 03, 2023 15:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 2 convertible bonds in Oxurion resulting in a EUR 50,000 capital increase. This is part of Atlas Special...
October 30, 2023 03:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 30, 2023 – 8.00 AM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
October 25, 2023 02:00 ET | Source: Oxurion NV

Oxurion Receives EUR 1.5 Million under Amended Atlas Funding Program; Total of EUR 3.5 Million in Unconditional Funding Allowing Company to Achieve Topline Data from KALAHARI Trial

Leuven, BELGIUM, Boston, MA, US – October 25, 2023 – 8 am CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with...
October 20, 2023 14:01 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
October 20, 2023 14:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notifications from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 20, 2023 – 8.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...
October 10, 2023 14:00 ET | Source: Oxurion NV

Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas

Regulated Information - Denominator Atlas Special Opportunities, LLC has converted 4 convertible bonds in Oxurion resulting in a EUR 100,000 capital increase. This is part of Atlas Special...
October 03, 2023 13:00 ET | Source: Oxurion NV

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Regulated Information Leuven, BELGIUM, Boston, MA, US – October 3, 2023 – 7.00 PM CET Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next generation standard of care...